![Terry Sivesind](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Terry Sivesind
Founder at Renovar, Inc.
Terry Sivesind active positions
Companies | Position | Start | End |
---|---|---|---|
Renovar, Inc.
![]() Renovar, Inc. Medical/Nursing ServicesHealth Services Renovar, Inc. develops and provides diagnostic tests for kidney disease and transplant monitoring based on protein biomarkers. The company was founded by Stuart J. Knechtle and Terry Sivesind in 1999 and is headquartered in Little Chute, WI. | Director/Board Member | 31/12/1998 | - |
Founder | 23/03/2010 | - | |
Wisconsin Investment Partners LLC
![]() Wisconsin Investment Partners LLC Investment ManagersFinance Wisconsin Investment Partners LLC (Wisconsin Investment Partners) is a venture capital firm founded in 2000 by Dick Leazer and Terry Sivesind. The firm is headquartered in Madison, Wisconsin. | Consultant / Advisor | 31/12/1999 | - |
Founder | 31/12/1999 | - |
Career history of Terry Sivesind
Former positions of Terry Sivesind
Companies | Position | Start | End |
---|---|---|---|
Cellectar, Inc.
![]() Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way. | Corporate Secretary | - | 31/03/2011 |
Treasurer | - | 31/03/2011 | |
Roche Madison, Inc.
![]() Roche Madison, Inc. Pharmaceuticals: MajorHealth Technology Roche Madison, Inc. provides gene transfer technologies to the pharmaceutical industry. The company was founded in 1995 by Jon Wolff, James Hagstrom and Vladimir Budker and is headquartered in Madison, WI. | Founder | - | - |
PanVera Corp. | Founder | - | - |
Metabiologics, Inc.
![]() Metabiologics, Inc. Chemicals: SpecialtyProcess Industries Metabiologics, Inc. manufactures serotypes of botulinum toxin. The company was founded by Mike Goodnough, Carl Malizio and Terry Sivesind and is headquartered in Madison, WI. | Founder | - | - |
Training of Terry Sivesind
University of Wisconsin | Masters Business Admin |
Statistics
International
United States | 8 |
Operational
Founder | 5 |
Director/Board Member | 1 |
Masters Business Admin | 1 |
Sectoral
Health Technology | 3 |
Health Services | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 6 |
---|---|
Renovar, Inc.
![]() Renovar, Inc. Medical/Nursing ServicesHealth Services Renovar, Inc. develops and provides diagnostic tests for kidney disease and transplant monitoring based on protein biomarkers. The company was founded by Stuart J. Knechtle and Terry Sivesind in 1999 and is headquartered in Little Chute, WI. | Health Services |
Cellectar, Inc.
![]() Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way. | Commercial Services |
Wisconsin Investment Partners LLC
![]() Wisconsin Investment Partners LLC Investment ManagersFinance Wisconsin Investment Partners LLC (Wisconsin Investment Partners) is a venture capital firm founded in 2000 by Dick Leazer and Terry Sivesind. The firm is headquartered in Madison, Wisconsin. | Finance |
Metabiologics, Inc.
![]() Metabiologics, Inc. Chemicals: SpecialtyProcess Industries Metabiologics, Inc. manufactures serotypes of botulinum toxin. The company was founded by Mike Goodnough, Carl Malizio and Terry Sivesind and is headquartered in Madison, WI. | Process Industries |
PanVera Corp. | Health Technology |
Roche Madison, Inc.
![]() Roche Madison, Inc. Pharmaceuticals: MajorHealth Technology Roche Madison, Inc. provides gene transfer technologies to the pharmaceutical industry. The company was founded in 1995 by Jon Wolff, James Hagstrom and Vladimir Budker and is headquartered in Madison, WI. | Health Technology |
- Stock Market
- Insiders
- Terry Sivesind
- Experience